FMC Corp

FMC announced a turnaround plan at the Jefferies Global Industrials Conference that includes debt reduction (expected net debt by end-2026: $2.6–2.7bn, about $1bn from disposals/financings), restructuring of production sites (completion planned Q1 2027) and commercialization of new products such as fluindapyr, Isoflex and Dodhylex. Tessenderlo’s 20% stake with a three-year lock-up is intended to support the de-leveraging plan. Management sees 2027 as the start of recovery but expects Rynaxypyr stabilization and market tests in H2 2026 to be decisive; around 1,000 jobs are to be cut as part of the restructuring. FMC also emphasizes stronger partnerships to improve R&D efficiency and a repositioning of the core business with the aim of restoring growth above the market. » Plus sur de.investing.com

FMC’s stock plunged in pre-market trading after the company’s adjusted operating result in the second quarter surprised positively, but it confirmed its full-year outlook. Analysts at JPMorgan and UBS warned this could lead to lower estimates for the second half of the year. Bernstein also criticized weaker treatment numbers in the U.S.; the stock lost more than eight percent on Tradegate. » Plus sur de.investing.com

FMC shares fell to a 52-week low of $10.55, down 74.28% year‑over‑year. The company carries $4.66 billion in debt and a negative free cash flow (-$219.8 million). Tessenderlo is investing $400 million for a 20% stake to help reduce debt; FMC is also selling a parcel in Delaware for about $114 million and has filed an EPA registration dossier for the herbicide Rimisoxafen. BMO Capital reiterates a "Market Perform" rating, citing planned asset sales and the 2026 outlook. » Plus sur de.investing.com